Prestige Consumer Healthcare Inc. (NYSE:PBH) Receives $93.33 Consensus Target Price from Brokerages

Shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) have received a consensus recommendation of “Moderate Buy” from the six research firms that are currently covering the firm, Marketbeat.com reports. Three analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average 1-year target price among brokerages that have covered the stock in the last year is $93.33.

PBH has been the subject of several research reports. Royal Bank of Canada raised shares of Prestige Consumer Healthcare to a “hold” rating in a report on Thursday, May 8th. Wall Street Zen raised shares of Prestige Consumer Healthcare from a “hold” rating to a “buy” rating in a report on Saturday, May 17th. Canaccord Genuity Group boosted their price objective on shares of Prestige Consumer Healthcare from $93.00 to $100.00 and gave the company a “buy” rating in a report on Friday, February 7th. DA Davidson boosted their price objective on shares of Prestige Consumer Healthcare from $95.00 to $104.00 and gave the company a “buy” rating in a report on Friday, February 7th. Finally, Oppenheimer boosted their price objective on shares of Prestige Consumer Healthcare from $87.00 to $93.00 and gave the company an “outperform” rating in a report on Thursday, February 13th.

Prestige Consumer Healthcare Stock Up 0.6%

Shares of Prestige Consumer Healthcare stock opened at $85.11 on Monday. The company has a debt-to-equity ratio of 0.56, a quick ratio of 2.20 and a current ratio of 3.68. The stock has a market capitalization of $4.21 billion, a PE ratio of 19.93, a price-to-earnings-growth ratio of 2.69 and a beta of 0.45. Prestige Consumer Healthcare has a 52-week low of $63.79 and a 52-week high of $90.04. The company has a 50-day simple moving average of $83.53 and a two-hundred day simple moving average of $82.52.

Prestige Consumer Healthcare (NYSE:PBH) last issued its earnings results on Thursday, May 8th. The company reported $1.32 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.30 by $0.02. The business had revenue of $296.52 million during the quarter, compared to analysts’ expectations of $289.36 million. Prestige Consumer Healthcare had a net margin of 19.13% and a return on equity of 12.36%. The business’s revenue for the quarter was up 7.0% compared to the same quarter last year. During the same period in the previous year, the company earned $1.02 earnings per share. On average, analysts anticipate that Prestige Consumer Healthcare will post 4.5 EPS for the current fiscal year.

Insider Buying and Selling at Prestige Consumer Healthcare

In other Prestige Consumer Healthcare news, SVP Mary Beth Fritz sold 1,678 shares of the company’s stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $90.00, for a total transaction of $151,020.00. Following the completion of the sale, the senior vice president now directly owns 17,157 shares of the company’s stock, valued at approximately $1,544,130. This represents a 8.91% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 1.60% of the stock is owned by corporate insiders.

Institutional Trading of Prestige Consumer Healthcare

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in PBH. Kestra Investment Management LLC purchased a new stake in Prestige Consumer Healthcare during the fourth quarter valued at approximately $27,000. CIBC Private Wealth Group LLC increased its holdings in Prestige Consumer Healthcare by 48.9% during the fourth quarter. CIBC Private Wealth Group LLC now owns 463 shares of the company’s stock valued at $34,000 after buying an additional 152 shares during the last quarter. Opal Wealth Advisors LLC bought a new position in shares of Prestige Consumer Healthcare in the first quarter worth approximately $38,000. Headlands Technologies LLC bought a new position in shares of Prestige Consumer Healthcare in the fourth quarter worth approximately $40,000. Finally, Geneos Wealth Management Inc. boosted its position in shares of Prestige Consumer Healthcare by 92.8% in the first quarter. Geneos Wealth Management Inc. now owns 559 shares of the company’s stock worth $48,000 after purchasing an additional 269 shares during the period. 99.95% of the stock is owned by hedge funds and other institutional investors.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.